Dog dander allergen-specific immunoglobulin E (Dog-specific IgE)

Dog dander allergen-specific immunoglobulin E (IgE) is a central mediator of Type I hypersensitivity reactions in individuals sensitized to Canis familiaris. These antibodies are produced by plasma cells and specifically recognize various dog-derived proteins, such as the lipocalins Can f 1, Can f 2, Can f 4, and Can f 6, as well as the prostatic kallikrein Can f 5 (PMID: 26073860). When these allergens are inhaled or come into contact with mucosal surfaces, they cross-link allergen-specific IgE bound to high-affinity FcεRI receptors on mast cells and basophils. This interaction triggers the immediate release of inflammatory mediators, leading to clinical symptoms of allergic rhinitis, conjunctivitis, and asthma (PMID: 30143322). Therapeutic interventions targeting this pathway include anti-IgE monoclonal antibodies like Omalizumab, which neutralize circulating IgE and reduce receptor density on effector cells (PMID: 28434616). Additionally, allergen-specific immunotherapy (AIT) utilizes standardized dog dander extracts to induce immune tolerance by shifting the immune response from a Th2-mediated allergic profile to a Th1 or regulatory T-cell (Treg) profile (PMID: 31103186). Accurate diagnosis and treatment monitoring often rely on measuring serum levels of these specific IgE antibodies or using component-resolved diagnostics to identify the specific proteins driving the allergic response.

Other names

Canis familiaris allergen-specific IgEDog sIgEAnti-dog IgECan f specific IgEHigh-affinity IgE receptor (FcεRI)

Neutralization of circulating IgE to prevent binding to FcεRI receptors on effector cells; downregulation of FcεRI expression on mast cells and basophils; induction of immune tolerance and IgG4 production through allergen-specific immunotherapy (PMID: 30143322, PMID: 28434616).